Dare Bioscience (DARE) Total Non-Current Liabilities (2013 - 2026)

Dare Bioscience (DARE) has 13 years of Total Non-Current Liabilities data on file, last reported at $24.2 million in Q4 2025.

• Quarterly Total Non-Current Liabilities rose 3.76% year-over-year to $24.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $24.2 million (up 3.76% YoY) and the FY2025 annual result came in at $24.2 million, up 3.76% from the prior year.
• Total Non-Current Liabilities advanced to $24.2 million in Q4 2025, from $22.7 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $32.7 million in Q4 2022 to a low of $6.1 million in Q2 2021.
• A 5-year average of $20.4 million and a median of $21.6 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2021 — Total Non-Current Liabilities soared 96.9% — and 2023, when it plunged 31.48%.
• Tracing DARE's Total Non-Current Liabilities over 5 years: stood at $17.1 million in 2021, then surged by 91.84% to $32.7 million in 2022, then slumped by 31.48% to $22.4 million in 2023, then climbed by 4.24% to $23.4 million in 2024, then increased by 3.76% to $24.2 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $24.2 million (Q4 2025), $22.7 million (Q3 2025), and $20.8 million (Q2 2025), per Business Quant data.